New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder

Authors

Leslie L. Citrome, New York Medical CollegeFollow
Bradley N. Gaynes
Joseph F. GoldbergFollow
Terence Ketter
James W. Murrough

DOI

10.4088/JCP.TK18061AS2C

Journal Title

The Journal of Clinical Psychiatry

First Page

TK18061AS2C

Document Type

Article

Publication Date

July 2019

Department

Psychiatry and Behavioral Sciences

Abstract

Listen to experts and view their slides from a panel session at the American Society of Clinical Psychopharmacology (ASCP) meeting, held on May 29, 2019, in Scottsdale, Arizona. Dr Murrough described the current understanding of depression etiology and new insights into antidepressant development. Dr Goldberg shared his expertise about whether antidepressant drugs with novel mechanisms of action can improve outcomes in patients with major depressive disorder. Dr Gaynes reviewed the link between major depressive disorder and elevated mortality risk and whether recovery from depression can reverse patients' mortality risk. Dr Citrome discussed current best practices and new medications for the treatment of depression. Finally, Dr Ketter provided his thoughts on his colleagues' presentations.

Recommended Citation

Citrome, L. L., Gaynes, B., Goldberg, J., Ketter, T., & Murrough, J. (2019). New Mechanisms, New Opportunities: Integrating Novel Antidepressants in the Treatment of Major Depressive Disorder. The Journal of Clinical Psychiatry, 80 (5), TK18061AS2C. https://doi.org/10.4088/JCP.TK18061AS2C